Business Context and Reporting Period
Company: Exagen Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2020
Reporting Period: Event date June 25, 2020; Amendment affects quarters ending June 30, 2020 through December 31, 2020.
Exagen Inc. is an emerging growth company incorporated in Delaware. The filing reports the entry into a material definitive agreement regarding the co-promotion of SIMPONI®.
Key Financial Metrics and Agreement Terms
This filing details a contractual amendment rather than a full financial statement. Key financial terms include:
- Adjusted Baseline: The predetermined average baseline for total prescribed units of SIMPONI® for remaining quarters in 2020 is adjusted to approximately 26,000 units per quarter.
- Promotion Fee Structure: The Company receives a tiered fee ranging from $750 to $1,250 per prescription based on incremental increases over the baseline.
- Minimum Fee Guarantee: For Q3 and Q4 2020, the Company is guaranteed a minimum promotion fee of $0.3 million per quarter.
- Fee Cap: Fees are capped at 5% above the adjusted predetermined baseline.
- Agreement Term: The Co-Promotion Agreement expires December 31, 2021, with an option to extend for 12 months.
Note: The filing text does not provide specific values for total revenue, net profit, cash flow, margins, debt, or liquidity for the period.
Material Changes Versus Prior Period
The primary material change is the adjustment to the Co-Promotion Agreement dated December 10, 2018. The baseline for prescribed units was lowered to approximately 26,000 units per quarter for the remainder of 2020. This adjustment was made in part due to the impact of COVID-19. Additionally, minimum fee guarantees and a fee cap were introduced for the third and fourth quarters of 2020, which were not present in the original agreement terms described.
Guidance, Outlook, and Risks
- Outlook: The baseline for 2021 is to be agreed upon by Exagen and Janssen Biotech, Inc. no later than November 30, 2020. If the agreement is extended into 2022, the baseline for that year will also be subject to future agreement.
- Risks and Contingencies: The adjustment to the baseline explicitly cites COVID-19 as a contributing factor. The fee structure is subject to adjustment under certain circumstances not fully detailed in this summary.
- Unusual Items: The introduction of a minimum fee guarantee ($0.3 million) and a cap (5% above baseline) for late 2020 represents a significant modification to the revenue recognition model for the co-promotion activity.
Important Facts for Investor Verification
- Verify the impact of the reduced baseline (26,000 units) on projected revenue for Q3 and Q4 2020 compared to prior guidance.
- Confirm the actual prescribed units of SIMPONI® in Q2 2020 to assess if the minimum fee guarantee was triggered.
- Monitor the upcoming Form 10-Q for the quarter ending June 30, 2020, which will contain the full text of the Amendment (with redactions).
- Track the negotiation status of the 2021 baseline, with a deadline of November 30, 2020.
- Assess the extent to which COVID-19 continues to influence prescription volumes and the potential for further baseline adjustments.